All In Biotech

NDA 020671 · Sandoz

Hycamtin

Topotecan Hydrochloride · Injection

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Oct 8, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

May 28, 1996

Approved uses

4

Original approval plus efficacy supplements

Registered trials

477

118 Phase 3, 54 recruiting

FAERS reports

6,942

6,366 serious, 1,654 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: MYELOSUPPRESSION HYCAMTIN can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts of greater than or equal to 1,500/mm 3 and platelet counts greater than or equal to 100,000/mm 3 . Monitor blood cell counts [see Warnings and Precautions ( 5.1 )] . WARNING: MYELOSUPPRESSION See full prescribing information for complete boxed warning. HYCAMTIN can cause severe myelosuppression. Administer first cycle only to patients with baseline neutrophil counts greater than or equal to 1,500/mm 3 and platelet counts greater than or equal to 100,000/mm 3 . Monitor blood cell counts ( 2.4 , 5.1 ).

What it is approved for

From the label in effect Jul 7, 2022.

HYCAMTIN for injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent ( 1.1 ) Patients with small cell lung cancer (SCLC) platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy, as a single agent ( 1.2 ) Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin ( 1.3 ) 1.1 Ovarian Cancer HYCAMTIN ® for injection, as a single agent, is indicated for the treatment of patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. 1.2 Small Cell Lung Cancer HYCAMTIN for injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first‑line chemotherapy. 1.3 Cervical Cancer HYCAMTIN for injection, in combination with cisplatin, is indicated for the treatment of patients with Stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment.

Mechanism: Topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks. Topotecan binds to the topoisomerase I‑DNA complex and prevents re-ligation of these single-strand breaks. The cytotoxicity of topotecan is thought to be due to double-strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double-strand breaks.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 14, 2006 Supplement 14 · Efficacy · priority review LabelLetter
  • Feb 26, 2003 Supplement 10 · Efficacy · priority review Other
  • Nov 30, 1998 Supplement 4 · Efficacy LabelReviewLetter
  • May 28, 1996 Original approval · Type 1 - New Molecular Entity · priority review Review
1 products under this application
  • HYCAMTIN · TOPOTECAN HYDROCHLORIDE EQ 4MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Topotecan" as an intervention, any sponsor and status, largest first.

All 477 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia603
  • anaemia580
  • off label use575
  • death573
  • neutropenia559
  • nausea477
  • disease progression457
  • thrombocytopenia453
  • pyrexia449
  • vomiting437
  • product use in unapproved indication377
  • fatigue337

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004138
2005216
2006123
2007185
2008159
2009201
2010238
2011259
2012313
2013231
2014301
2015394
2016397
2017347
2018408
2019340
2020473
2021490
2022430
2023355
2024344
2025396
2026203

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 785 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.